Research & Development
CTI BioPharma anticipates USD10m in milestone payment for TRISENOX in February 2018
18 January 2018 -

CTI BioPharma Corp (NASDAQ:CTIC)(MTA:CTIC) stated on Wednesday that it expects to receive USD10m in milestone payment for TRISENOX from Teva Pharmaceutical Industries Ltd in February 2018.

According to CTI BioPharma Corp, the expected milestone payment is related to the US Food and Drug Administration's approval of TRISENOX (arsenic trioxide) for first line treatment of acute promyelocytic leukemia.

Under the terms of a prior acquisition agreement for TRISENOX with Teva, CTI BioPharma is eligible to receive up to an additional USD50m in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX.

Headquartered in Seattle, Washington, CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.